IL6 blockade is therapeutic in some preclinical models of IBD, although it has been assumed that the therapeutic mechanism likely was attributable to limitation of T-cell–mediated pathology27, 28, 29, 30 because IL6 contributes to intestinal Th17 differentiation.31 Here, IL6 is linked to inflammatory bowel disease.